[ad_1]
SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) – Hagens Berman urges Athira Pharma, Inc. (ATHA) investors with large losses submit your losses now. A class action lawsuit in securities has been filed and some investors may have interesting claims.
Class period: Sep 18, 2020 – Jun 17, 2021
Lead applicant’s deadline: August 24, 2021
Visit: www.hbsslaw.com/investor-fraud/ATHA
Contact a lawyer now: [email protected]
844-916-0895
Athira Pharma, Inc. (ATHA, Financial) Class action in securities:
Since its IPO in September 2020, Athira and senior management have repeatedly emphasized the importance of CEO Leen Kawas’ doctoral research for the company’s product candidates intended to treat Alzheimer’s disease.
According to the lawsuit, the defendants did not disclose to investors that the research carried out by Kawas, which formed the basis of Athira’s product candidates and intellectual property, was tainted with scientific fault by Kawas, including the manipulation of key data.
Investors began to learn the truth, according to the complaint, after the market closed on June 17, 2021, when the company announced that its board of directors had put Kawas on temporary leave pending its review of research published by Kawas at the time. that he was at Washington State University. The same day, STAT News reported that Athira’s decision was based on allegations of altered images in four separate articles of which Kawas was the lead author. STAT reported that Washington State University is also conducting a review and “[t]it would have altered images questioning the validity of entire studies, several Alzheimer’s experts have said.
More, Barron reported Stifel analyst Paul Matteis said “[w]e really don’t know how to deal with this development “and”[t]The scientific hypothesis behind Athira got out of work [that] Dr Kawas did his graduate studies, so there is a risk here that anything that emerges from this investigation could have clear negative implications for how we / investors view the asset and / or the credibility of management. ”
This news caused Athira’s stock price to drop.
“We focus on investor losses and prove that defendants knew that Kawas’ doctoral research did not support the company’s lead product candidate ATH-1017,” said Reed Kathrein, Hagens Berman’s partner who heads the company. ‘investigation.
If you are an Athira investor and have significant losses, or have knowledge that may assist the company’s investigation, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Those with non-public information regarding Athira should consider their options to assist with the investigation or take advantage of the SEC’s whistleblower program. Under the new program, whistleblowers who provide original information can receive rewards totaling up to 30% of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a national law firm with eight offices in eight cities across the country and over eighty lawyers. The firm represents investors, whistleblowers, workers and consumers in complex litigation. To learn more about the company and its successes, visit hbsslaw.com. For the latest news, visit our writing or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 844-916-0895
[ad_2]
